Microcap Ledger Bone Biologics Corp $BBLG
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- Headquarters
- Burlington, MA
- Fiscal year end
- December 31
- Shares outstanding
- 2,756,057 [10-Q 2026-08-14]
What the company doesAI summary of filing
Bone Biologics Corp is a clinical-stage medical device company developing NELL-1, a recombinant human protein combined with demineralized bone matrix (DBM), for bone regeneration in spinal fusion procedures. The company has exclusively licensed NELL-1 technology from UCLA and is currently conducting a first-in-man pilot clinical study in Australia evaluating safety and effectiveness of its NB1 device in patients undergoing lumbar spinal fusion for degenerative disc disease. The company is pre-revenue and plans to seek FDA premarket approval through a pivotal clinical trial before commercialization in the United States. Bone Biologics generates no revenue and relies on capital funding to advance its product through regulatory and clinical development. [10-K 2026-03-02]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$1.54M | −$1.32M | $4.03M | [10-Q 2026-08-14] |
| FY ended Dec 2025 | — | −$3.11M | −$2.69M | $5.33M | [DEF 14A 2026-08-28] |
| FY ended Dec 2024 | — | −$4.11M | −$4.12M | $3.33M | [DEF 14A 2026-08-28] |
- Quarterly cash burn
- −$661.4K
- Cash runway Estimate
- ~18.3 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-14 | 2,463,534 | [10-Q 2024-11-14] |
| 2025-02-19 | 3,271,042 | [10-K 2025-02-26] |
| 2025-05-01 | 3,271,042 | [10-Q 2025-05-12] |
| 2025-08-14 | 1,795,260 | [10-Q 2025-08-14] |
| 2025-11-14 | 1,795,260 | [10-Q 2025-11-14] |
| 2026-02-23 | 1,795,260 | [10-K 2026-03-02] |
| 2026-05-14 | 1,795,260 | [10-Q 2026-05-14] |
| 2026-08-14 | 2,756,057 | [10-Q 2026-08-14] |
- Shelf registration
- S-3 filed 2026-07-17; declared effective 2026-07-24 [S-3 2026-07-17]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-09-16. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-09-16 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-09-16] |
| 2025-04-11 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-04-11] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-29 | 8-K | Shareholder vote results |
| 2026-09-16 | 8-K | Listing notice or transfer |
| 2026-08-28 | DEF 14A | Proxy statement |
| 2026-08-18 | PRE 14A | Proxy statement |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-07-24 | 424B3 | Prospectus or prospectus supplement |
| 2026-07-23 | 8-K | Regulation FD disclosure |
| 2026-07-17 | S-3 | Registration statement |
| 2026-07-16 | 8-K | Other events |
| 2026-07-09 | 8-K | Material agreement entered; Unregistered sale of equity; Other events |
| 2026-07-02 | DEF 14A | Proxy statement |
| 2026-05-14 | 10-Q | Quarterly report |
Alerts for $BBLG
Email me when Bone Biologics Corp files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.